Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Papadopoulos

Showing results (271-280 of 288) with videos related to

Pageof 29
Sort By:
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Cancer|April 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignanciesTae Min Kim, Stephen K Williamson, Kyriakos P Papadopoulos, et al.
Cancer Cell|November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsAung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in <i>NUP98</i>-rearranged leukemiaMasayuki Umeda, Ryan Hiltenbrand, Nicole L Michmerhuizen, et al.
Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
Blood|July 23, 2025
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged LeukemiaMasayuki Umeda, Ryan Lea Hiltenbrand, Nicole L Michmerhuizen, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Karl D Lewis, Amy Weise, et al.
Pageof 29

Showing results (271-280 of 288) with videos related to

Sort By:
Pageof 29
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Cancer|April 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignanciesTae Min Kim, Stephen K Williamson, Kyriakos P Papadopoulos, et al.
Cancer Cell|November 14, 2018
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8<sup>+</sup> T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsAung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in <i>NUP98</i>-rearranged leukemiaMasayuki Umeda, Ryan Hiltenbrand, Nicole L Michmerhuizen, et al.
Cancer Discovery|May 25, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsAmita Patnaik, Lee S Rosen, Sara M Tolaney, et al.
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
Blood|July 23, 2025
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged LeukemiaMasayuki Umeda, Ryan Lea Hiltenbrand, Nicole L Michmerhuizen, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Karl D Lewis, Amy Weise, et al.
Pageof 29